Aethlon Medical (NASDAQ: AEMD) reportedly plays a part in a “60 Minutes” segment on CTE in combat veterans that’s airing Sunday.
The story says combat veterans exposed to bomb blasts are being diagnosed with CTE much like NFL players with a history of concussions.
Aethlon shares traded up as much as 35 percent in Friday trading. The stock closed Friday at $1.56.
Seeking Alpha reports that Aethlon is the majority owner of Exosome Sciences, which has found a biomarker, TauSome, that could be used to detect CTE in sufferers who are still living.
CTE, which a study found in 110 of the 111 brains of former NFL players, is diagnosed in 65 percent of combat veterans who were studied, according to CBS Corporation (NYSE: CBS).
7 Stocks To Watch Ahead Of The 60 Minutes DEA-Opioid Exposé
See more from Benzinga
- Detroit's Tallest Building Breaks Ground: 'This Is Going To Be A Site Of Our Recovery'
- Nvidia Invests In Bay Area Artificial Intelligence Startup
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.